Novo Nordisk sues Eli Lilly over "misleading advertising" of Zepbound versus Ozempic and Wegovy

Novo Nordisk has filed a lawsuit against Eli Lilly in a New Jersey federal court, accusing the U.S. pharmaceutical company of using misleading advertising to promote its weight-loss and diabetes drugs Mounjaro and Zepbound. The Danish drugmaker, which markets Ozempic and Wegovy, claims that Eli Lilly's marketing falsely suggests its products are more effective for weight loss. The lawsuit centers on comparative efficacy claims in a highly competitive market for GLP-1 receptor agonists, which have seen explosive demand. Novo Nordisk seeks to halt the allegedly deceptive ads and may pursue damages. The case highlights intensifying rivalry in the obesity and diabetes treatment sector, a multi-billion-dollar market. Legal experts expect a protracted dispute over clinical data interpretation and advertising standards.

Global Impact

The lawsuit has industry-specific implications for the pharmaceutical sector, particularly the GLP-1 receptor agonist market. A ruling against Eli Lilly could force changes in how drugmakers compare their products in advertising, potentially raising marketing costs and altering competitive dynamics.